Overview

IMPORTANT SAFETY INFORMATION: The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation. Please see full Prescribing Information at https://www.tyrvaya-pro.com/files/prescribing-information.pdf To report an adverse event, please contact: 1-877-EYE-0123 © 2022 Oyster Point Pharma, Inc. Tyrvaya® and the Tyrvaya logo are trademarks of Oyster Point Pharma, Inc. in the United States and certain jurisdictions. All rights reserved. OP-TYR-001478 4/22